x
Filter:
Filters applied
- EMAS Position Statements and Clinical GuidesRemove EMAS Position Statements and Clinical Guides filter
- Postmenopausal osteoporosisRemove Postmenopausal osteoporosis filter
Author
- Lambrinoudaki, Irene2
- Rees, Margaret2
- Brincat, Mark1
- Cano, Antonio1
- Chedraui, Peter1
- Erel, C Tamer1
- Gambacciani, Marco1
- Goulis, Dimitrios G1
- Lopes, Patrice1
- Mishra, Gita1
- Moen, Mette H1
- Mueck, Alfred1
- Palacios, Santiago1
- Rozenberg, Serge1
- Schenck-Gustafsson, Karin1
- Senturk, Levent M1
- Simoncini, Tommaso1
- Stevenson, John C1
- Stute, Petra1
- Tremollieres, Florence1
- Tuomikoski, Pauliina1
- Vujovic, Svetlana1
EMAS Position Statements and Clincial Guides
2 Results
- Research Article
Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide
MaturitasVol. 107p7–12Published online: October 3, 2017- Antonio Cano
- Peter Chedraui
- Dimitrios G. Goulis
- Patrice Lopes
- Gita Mishra
- Alfred Mueck
- and others
Cited in Scopus: 78Osteoporosis is a chronic disease with a growing prevalence due to the increase in life expectancy [1]. It is far more common in women than in men, and its prevalence increases markedly after the menopause. Approximately 30% of all postmenopausal women have osteoporosis in the United States and Europe, and at least 40% of these women will suffer one or more fragility fractures [2]. As with other chronic diseases affecting modern societies, such as cardiovascular disease and cancer, risk reduction is a preferred strategy. - Research Article
EMAS clinical guide: Selective estrogen receptor modulators for postmenopausal osteoporosis
MaturitasVol. 71Issue 2p194–198Published online: November 24, 2011- Santiago Palacios
- Mark Brincat
- C. Tamer Erel
- Marco Gambacciani
- Irene Lambrinoudaki
- Mette H. Moen
- and others
Cited in Scopus: 16Osteoporosis and the resulting fractures are major public health issues as the world population is ageing. Various therapies such as bisphosphonates, strontium ranelate and more recently denosumab are available. This clinical guide provides the evidence for the clinical use of selective estrogen modulators (SERMs) in the management of osteoporosis in postmenopausal women.
